nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—LIPF—digestive system—systemic scleroderma	0.0276	0.139	CbGeAlD
Orlistat—DAGLA—tendon—systemic scleroderma	0.017	0.0855	CbGeAlD
Orlistat—PLA2G7—connective tissue—systemic scleroderma	0.0154	0.0779	CbGeAlD
Orlistat—PNLIP—connective tissue—systemic scleroderma	0.0136	0.0685	CbGeAlD
Orlistat—DAGLB—tendon—systemic scleroderma	0.0131	0.0663	CbGeAlD
Orlistat—DAGLB—lung—systemic scleroderma	0.0115	0.0582	CbGeAlD
Orlistat—PLA2G7—tendon—systemic scleroderma	0.0106	0.0536	CbGeAlD
Orlistat—PNLIP—Retinoid metabolism and transport—HSPG2—systemic scleroderma	0.0102	0.0623	CbGpPWpGaD
Orlistat—FASN—Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.0102	0.481	CbGdCrCtD
Orlistat—ABHD16A—tendon—systemic scleroderma	0.00996	0.0503	CbGeAlD
Orlistat—PNLIP—digestive system—systemic scleroderma	0.00981	0.0495	CbGeAlD
Orlistat—ABHD12—tendon—systemic scleroderma	0.00934	0.0471	CbGeAlD
Orlistat—PLA2G7—lung—systemic scleroderma	0.00932	0.047	CbGeAlD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—CCL2—systemic scleroderma	0.00923	0.0564	CbGpPWpGaD
Orlistat—ABHD16A—lung—systemic scleroderma	0.00874	0.0441	CbGeAlD
Orlistat—PNLIP—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.00871	0.0532	CbGpPWpGaD
Orlistat—ABHD12—lung—systemic scleroderma	0.00819	0.0413	CbGeAlD
Orlistat—PNLIP—lung—systemic scleroderma	0.00819	0.0413	CbGeAlD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—IL1B—systemic scleroderma	0.007	0.0427	CbGpPWpGaD
Orlistat—FASN—lung—systemic scleroderma	0.00688	0.0347	CbGeAlD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—MMP9—systemic scleroderma	0.0066	0.0403	CbGpPWpGaD
Orlistat—FASN—p73 transcription factor network—GDF15—systemic scleroderma	0.00657	0.0401	CbGpPWpGaD
Orlistat—PLA2G7—Peptide hormone metabolism—ACE—systemic scleroderma	0.00643	0.0392	CbGpPWpGaD
Orlistat—FASN—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00576	0.272	CbGdCrCtD
Orlistat—PLA2G4A—connective tissue—systemic scleroderma	0.00548	0.0276	CbGeAlD
Orlistat—PNLIP—Diseases associated with visual transduction—HSPG2—systemic scleroderma	0.00521	0.0318	CbGpPWpGaD
Orlistat—PLA2G4A—smooth muscle tissue—systemic scleroderma	0.00501	0.0253	CbGeAlD
Orlistat—PLA2G4A—tendon—systemic scleroderma	0.00377	0.019	CbGeAlD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.00364	0.0222	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.00364	0.0222	CbGpPWpGaD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—IL1A—systemic scleroderma	0.00348	0.0213	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.00339	0.0207	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.00339	0.0207	CbGpPWpGaD
Orlistat—PLA2G4A—lung—systemic scleroderma	0.0033	0.0167	CbGeAlD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.00309	0.0189	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.00309	0.0189	CbGpPWpGaD
Orlistat—PLA2G4A—Enalapril—Captopril—systemic scleroderma	0.00247	0.116	CbGdCrCtD
Orlistat—PLA2G4A—Endothelins—COL1A2—systemic scleroderma	0.0022	0.0134	CbGpPWpGaD
Orlistat—PLA2G4A—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00215	0.0131	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—EDN1—systemic scleroderma	0.00198	0.0121	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—EDN1—systemic scleroderma	0.00198	0.0121	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—SELP—systemic scleroderma	0.00187	0.0114	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SELP—systemic scleroderma	0.00187	0.0114	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.00177	0.0108	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.00177	0.0108	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—RHOB—systemic scleroderma	0.00175	0.0107	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—RHOB—systemic scleroderma	0.00175	0.0107	CbGpPWpGaD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	0.00168	0.0102	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—CSK—systemic scleroderma	0.00159	0.00973	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—CSK—systemic scleroderma	0.00159	0.00973	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ITGAM—systemic scleroderma	0.0015	0.00914	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—ITGAM—systemic scleroderma	0.0015	0.00914	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00139	0.0085	CbGpPWpGaD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—systemic scleroderma	0.00137	0.0644	CbGdCrCtD
Orlistat—CYP3A4—digestive system—systemic scleroderma	0.00131	0.00659	CbGeAlD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.00124	0.0076	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.00123	0.00749	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—ACE—systemic scleroderma	0.00121	0.00741	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—EDN1—systemic scleroderma	0.00119	0.00726	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—RHOB—systemic scleroderma	0.00111	0.00675	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—RHOB—systemic scleroderma	0.00111	0.00675	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.00107	0.00651	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—RHOB—systemic scleroderma	0.001	0.00613	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—RHOB—systemic scleroderma	0.001	0.00613	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—MMP1—systemic scleroderma	0.001	0.0061	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000943	0.00576	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000915	0.00558	CbGpPWpGaD
Orlistat—PNLIP—Disease—SMAD7—systemic scleroderma	0.000907	0.00554	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.00088	0.00537	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000854	0.00521	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFBI—systemic scleroderma	0.00083	0.00506	CbGpPWpGaD
Orlistat—PLA2G4A—Enalapril—Lisinopril—systemic scleroderma	0.000814	0.0383	CbGdCrCtD
Orlistat—PLA2G7—Metabolism of proteins—MMP1—systemic scleroderma	0.000779	0.00476	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000778	0.00475	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SMAD7—systemic scleroderma	0.000767	0.00468	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SMAD7—systemic scleroderma	0.000767	0.00468	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—MMP1—systemic scleroderma	0.000751	0.00458	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—MMP1—systemic scleroderma	0.000751	0.00458	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000746	0.00455	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000698	0.00426	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000698	0.00426	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000698	0.00426	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000667	0.00407	CbGpPWpGaD
Orlistat—PNLIP—Disease—HSPG2—systemic scleroderma	0.000662	0.00404	CbGpPWpGaD
Orlistat—FASN—Disease—SMAD7—systemic scleroderma	0.000642	0.00392	CbGpPWpGaD
Orlistat—PNLIP—Disease—CSK—systemic scleroderma	0.000639	0.0039	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SMAD7—systemic scleroderma	0.000635	0.00388	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—CCL2—systemic scleroderma	0.000634	0.00387	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet homeostasis—NOS3—systemic scleroderma	0.000611	0.00373	CbGpPWpGaD
Orlistat—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000611	0.000991	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00061	0.000988	CcSEcCtD
Orlistat—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000607	0.000985	CcSEcCtD
Orlistat—Discomfort—Lisinopril—systemic scleroderma	0.000606	0.000983	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—MMP2—systemic scleroderma	0.000603	0.00368	CbGpPWpGaD
Orlistat—Dyspepsia—Leflunomide—systemic scleroderma	0.000603	0.000977	CcSEcCtD
Orlistat—Pancreatitis—Prednisone—systemic scleroderma	0.000603	0.000977	CcSEcCtD
Orlistat—Vomiting—Mometasone—systemic scleroderma	0.000601	0.000975	CcSEcCtD
Orlistat—PNLIP—Disease—CD247—systemic scleroderma	0.000601	0.00367	CbGpPWpGaD
Orlistat—Dry mouth—Lisinopril—systemic scleroderma	0.0006	0.000973	CcSEcCtD
Orlistat—Sweating increased—Prednisone—systemic scleroderma	0.000599	0.000971	CcSEcCtD
Orlistat—Feeling abnormal—Azathioprine—systemic scleroderma	0.000598	0.000969	CcSEcCtD
Orlistat—Rash—Mometasone—systemic scleroderma	0.000596	0.000967	CcSEcCtD
Orlistat—Asthenia—Captopril—systemic scleroderma	0.000596	0.000967	CcSEcCtD
Orlistat—Dermatitis—Mometasone—systemic scleroderma	0.000596	0.000966	CcSEcCtD
Orlistat—Decreased appetite—Leflunomide—systemic scleroderma	0.000595	0.000965	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000595	0.000965	CcSEcCtD
Orlistat—Osteoarthritis—Methotrexate—systemic scleroderma	0.000594	0.000963	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—RHOB—systemic scleroderma	0.000593	0.00362	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RHOB—systemic scleroderma	0.000593	0.00362	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000593	0.000961	CcSEcCtD
Orlistat—Headache—Mometasone—systemic scleroderma	0.000593	0.000961	CcSEcCtD
Orlistat—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000591	0.000959	CcSEcCtD
Orlistat—Insomnia—Mycophenolic acid—systemic scleroderma	0.000591	0.000958	CcSEcCtD
Orlistat—Fatigue—Leflunomide—systemic scleroderma	0.00059	0.000957	CcSEcCtD
Orlistat—Oedema—Lisinopril—systemic scleroderma	0.000588	0.000954	CcSEcCtD
Orlistat—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000588	0.000954	CcSEcCtD
Orlistat—Pruritus—Captopril—systemic scleroderma	0.000588	0.000953	CcSEcCtD
Orlistat—FASN—Disease—TGFBI—systemic scleroderma	0.000587	0.00358	CbGpPWpGaD
Orlistat—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000587	0.000951	CcSEcCtD
Orlistat—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000586	0.00095	CcSEcCtD
Orlistat—Pain—Leflunomide—systemic scleroderma	0.000586	0.000949	CcSEcCtD
Orlistat—Infection—Lisinopril—systemic scleroderma	0.000585	0.000948	CcSEcCtD
Orlistat—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000577	0.000936	CcSEcCtD
Orlistat—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000575	0.000932	CcSEcCtD
Orlistat—Abdominal pain—Azathioprine—systemic scleroderma	0.000573	0.000929	CcSEcCtD
Orlistat—Body temperature increased—Azathioprine—systemic scleroderma	0.000573	0.000929	CcSEcCtD
Orlistat—Skin disorder—Lisinopril—systemic scleroderma	0.000572	0.000927	CcSEcCtD
Orlistat—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00057	0.000924	CcSEcCtD
Orlistat—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000569	0.000922	CcSEcCtD
Orlistat—Diarrhoea—Captopril—systemic scleroderma	0.000568	0.000922	CcSEcCtD
Orlistat—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000568	0.000921	CcSEcCtD
Orlistat—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000568	0.00092	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—EDN1—systemic scleroderma	0.000564	0.00345	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—EDN1—systemic scleroderma	0.000564	0.00345	CbGpPWpGaD
Orlistat—Feeling abnormal—Leflunomide—systemic scleroderma	0.000564	0.000915	CcSEcCtD
Orlistat—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000564	0.000914	CcSEcCtD
Orlistat—Fatigue—Mycophenolic acid—systemic scleroderma	0.000563	0.000913	CcSEcCtD
Orlistat—Nausea—Mometasone—systemic scleroderma	0.000562	0.000911	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—MMP9—systemic scleroderma	0.00056	0.00342	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00056	0.000908	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—HSPG2—systemic scleroderma	0.000559	0.00341	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HSPG2—systemic scleroderma	0.000559	0.00341	CbGpPWpGaD
Orlistat—Pain—Mycophenolic acid—systemic scleroderma	0.000559	0.000906	CcSEcCtD
Orlistat—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000558	0.000905	CcSEcCtD
Orlistat—PNLIP—Metabolism—HSPG2—systemic scleroderma	0.000554	0.00338	CbGpPWpGaD
Orlistat—Cough—Mycophenolate mofetil—systemic scleroderma	0.000551	0.000894	CcSEcCtD
Orlistat—Dizziness—Captopril—systemic scleroderma	0.000549	0.000891	CcSEcCtD
Orlistat—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000547	0.000887	CcSEcCtD
Orlistat—Depression—Prednisone—systemic scleroderma	0.000546	0.000886	CcSEcCtD
Orlistat—DAGLB—Hemostasis—NOS3—systemic scleroderma	0.000544	0.00332	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—NOS3—systemic scleroderma	0.000544	0.00332	CbGpPWpGaD
Orlistat—Urticaria—Leflunomide—systemic scleroderma	0.000544	0.000882	CcSEcCtD
Orlistat—Body temperature increased—Leflunomide—systemic scleroderma	0.000541	0.000878	CcSEcCtD
Orlistat—Abdominal pain—Leflunomide—systemic scleroderma	0.000541	0.000878	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CSK—systemic scleroderma	0.00054	0.0033	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CSK—systemic scleroderma	0.00054	0.0033	CbGpPWpGaD
Orlistat—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000538	0.000873	CcSEcCtD
Orlistat—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000872	CcSEcCtD
Orlistat—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000872	CcSEcCtD
Orlistat—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000537	0.000871	CcSEcCtD
Orlistat—Breast disorder—Methotrexate—systemic scleroderma	0.000537	0.000871	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000536	0.000869	CcSEcCtD
Orlistat—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000536	0.000869	CcSEcCtD
Orlistat—Hypersensitivity—Azathioprine—systemic scleroderma	0.000534	0.000866	CcSEcCtD
Orlistat—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000534	0.000866	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000534	0.000866	CcSEcCtD
Orlistat—Insomnia—Lisinopril—systemic scleroderma	0.000532	0.000863	CcSEcCtD
Orlistat—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000531	0.000862	CcSEcCtD
Orlistat—Paraesthesia—Lisinopril—systemic scleroderma	0.000528	0.000857	CcSEcCtD
Orlistat—Vomiting—Captopril—systemic scleroderma	0.000528	0.000857	CcSEcCtD
Orlistat—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000526	0.000853	CcSEcCtD
Orlistat—Rash—Captopril—systemic scleroderma	0.000524	0.000849	CcSEcCtD
Orlistat—Dermatitis—Captopril—systemic scleroderma	0.000523	0.000849	CcSEcCtD
Orlistat—Headache—Captopril—systemic scleroderma	0.000521	0.000844	CcSEcCtD
Orlistat—Dyspepsia—Lisinopril—systemic scleroderma	0.000518	0.00084	CcSEcCtD
Orlistat—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000516	0.000837	CcSEcCtD
Orlistat—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000516	0.000837	CcSEcCtD
Orlistat—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000516	0.000836	CcSEcCtD
Orlistat—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000516	0.000836	CcSEcCtD
Orlistat—Asthma—Methotrexate—systemic scleroderma	0.000514	0.000833	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—EDN1—systemic scleroderma	0.000513	0.00313	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EDN1—systemic scleroderma	0.000513	0.00313	CbGpPWpGaD
Orlistat—Infection—Mycophenolate mofetil—systemic scleroderma	0.000512	0.00083	CcSEcCtD
Orlistat—Decreased appetite—Lisinopril—systemic scleroderma	0.000511	0.000829	CcSEcCtD
Orlistat—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000508	0.000824	CcSEcCtD
Orlistat—Fatigue—Lisinopril—systemic scleroderma	0.000507	0.000823	CcSEcCtD
Orlistat—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000506	0.00082	CcSEcCtD
Orlistat—Hypersensitivity—Leflunomide—systemic scleroderma	0.000505	0.000818	CcSEcCtD
Orlistat—Pancreatitis—Methotrexate—systemic scleroderma	0.000504	0.000816	CcSEcCtD
Orlistat—Pain—Lisinopril—systemic scleroderma	0.000503	0.000816	CcSEcCtD
Orlistat—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000501	0.000812	CcSEcCtD
Orlistat—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000498	0.000808	CcSEcCtD
Orlistat—Diarrhoea—Azathioprine—systemic scleroderma	0.000496	0.000804	CcSEcCtD
Orlistat—Haemoglobin—Prednisone—systemic scleroderma	0.000494	0.000802	CcSEcCtD
Orlistat—Nausea—Captopril—systemic scleroderma	0.000494	0.0008	CcSEcCtD
Orlistat—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000492	0.000798	CcSEcCtD
Orlistat—Haemorrhage—Prednisone—systemic scleroderma	0.000492	0.000798	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—RHOB—systemic scleroderma	0.000491	0.003	CbGpPWpGaD
Orlistat—Asthenia—Leflunomide—systemic scleroderma	0.000491	0.000797	CcSEcCtD
Orlistat—Feeling abnormal—Lisinopril—systemic scleroderma	0.000485	0.000786	CcSEcCtD
Orlistat—Pruritus—Leflunomide—systemic scleroderma	0.000484	0.000786	CcSEcCtD
Orlistat—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000481	0.00078	CcSEcCtD
Orlistat—Dizziness—Azathioprine—systemic scleroderma	0.00048	0.000777	CcSEcCtD
Orlistat—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000477	0.000774	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—SELP—systemic scleroderma	0.000471	0.00288	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00047	0.000762	CcSEcCtD
Orlistat—Asthenia—Mycophenolic acid—systemic scleroderma	0.000469	0.00076	CcSEcCtD
Orlistat—Diarrhoea—Leflunomide—systemic scleroderma	0.000469	0.00076	CcSEcCtD
Orlistat—FASN—Disease—HSPG2—systemic scleroderma	0.000468	0.00286	CbGpPWpGaD
Orlistat—Urticaria—Lisinopril—systemic scleroderma	0.000467	0.000758	CcSEcCtD
Orlistat—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000466	0.000756	CcSEcCtD
Orlistat—Abdominal pain—Lisinopril—systemic scleroderma	0.000465	0.000754	CcSEcCtD
Orlistat—Body temperature increased—Lisinopril—systemic scleroderma	0.000465	0.000754	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—HSPG2—systemic scleroderma	0.000463	0.00283	CbGpPWpGaD
Orlistat—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000463	0.000751	CcSEcCtD
Orlistat—Pruritus—Mycophenolic acid—systemic scleroderma	0.000462	0.000749	CcSEcCtD
Orlistat—Vomiting—Azathioprine—systemic scleroderma	0.000461	0.000748	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—systemic scleroderma	0.000458	0.000742	CcSEcCtD
Orlistat—Infestation—Methotrexate—systemic scleroderma	0.000458	0.000742	CcSEcCtD
Orlistat—Rash—Azathioprine—systemic scleroderma	0.000457	0.000741	CcSEcCtD
Orlistat—Dermatitis—Azathioprine—systemic scleroderma	0.000457	0.000741	CcSEcCtD
Orlistat—Depression—Methotrexate—systemic scleroderma	0.000457	0.00074	CcSEcCtD
Orlistat—Headache—Azathioprine—systemic scleroderma	0.000454	0.000737	CcSEcCtD
Orlistat—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000454	0.000736	CcSEcCtD
Orlistat—Dizziness—Leflunomide—systemic scleroderma	0.000453	0.000734	CcSEcCtD
Orlistat—FASN—Disease—CSK—systemic scleroderma	0.000452	0.00276	CbGpPWpGaD
Orlistat—Renal failure—Methotrexate—systemic scleroderma	0.00045	0.00073	CcSEcCtD
Orlistat—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000448	0.000727	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CSK—systemic scleroderma	0.000448	0.00273	CbGpPWpGaD
Orlistat—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000447	0.000725	CcSEcCtD
Orlistat—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000445	0.000722	CcSEcCtD
Orlistat—Immune system disorder—Prednisone—systemic scleroderma	0.000444	0.00072	CcSEcCtD
Orlistat—Pain—Mycophenolate mofetil—systemic scleroderma	0.000441	0.000715	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—RHOB—systemic scleroderma	0.00044	0.00269	CbGpPWpGaD
Orlistat—Vomiting—Leflunomide—systemic scleroderma	0.000435	0.000706	CcSEcCtD
Orlistat—Alopecia—Prednisone—systemic scleroderma	0.000435	0.000705	CcSEcCtD
Orlistat—Hypersensitivity—Lisinopril—systemic scleroderma	0.000434	0.000703	CcSEcCtD
Orlistat—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000433	0.000702	CcSEcCtD
Orlistat—Dizziness—Mycophenolic acid—systemic scleroderma	0.000432	0.0007	CcSEcCtD
Orlistat—Rash—Leflunomide—systemic scleroderma	0.000432	0.0007	CcSEcCtD
Orlistat—Dermatitis—Leflunomide—systemic scleroderma	0.000431	0.000699	CcSEcCtD
Orlistat—Mental disorder—Prednisone—systemic scleroderma	0.000431	0.000699	CcSEcCtD
Orlistat—Nausea—Azathioprine—systemic scleroderma	0.000431	0.000698	CcSEcCtD
Orlistat—Headache—Leflunomide—systemic scleroderma	0.000429	0.000696	CcSEcCtD
Orlistat—Malnutrition—Prednisone—systemic scleroderma	0.000428	0.000694	CcSEcCtD
Orlistat—FASN—Disease—CD247—systemic scleroderma	0.000425	0.0026	CbGpPWpGaD
Orlistat—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000425	0.000689	CcSEcCtD
Orlistat—Asthenia—Lisinopril—systemic scleroderma	0.000422	0.000684	CcSEcCtD
Orlistat—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000422	0.000684	CcSEcCtD
Orlistat—PNLIP—Metabolism—CTGF—systemic scleroderma	0.00042	0.00256	CbGpPWpGaD
Orlistat—Pruritus—Lisinopril—systemic scleroderma	0.000416	0.000675	CcSEcCtD
Orlistat—Vomiting—Mycophenolic acid—systemic scleroderma	0.000415	0.000673	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—systemic scleroderma	0.000413	0.00067	CcSEcCtD
Orlistat—Rash—Mycophenolic acid—systemic scleroderma	0.000412	0.000668	CcSEcCtD
Orlistat—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000412	0.000667	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—systemic scleroderma	0.000411	0.000667	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—systemic scleroderma	0.000411	0.000667	CcSEcCtD
Orlistat—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00041	0.000664	CcSEcCtD
Orlistat—Headache—Mycophenolic acid—systemic scleroderma	0.000409	0.000664	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—systemic scleroderma	0.000408	0.000662	CcSEcCtD
Orlistat—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000408	0.000661	CcSEcCtD
Orlistat—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000408	0.000661	CcSEcCtD
Orlistat—Nausea—Leflunomide—systemic scleroderma	0.000407	0.000659	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000406	0.000658	CcSEcCtD
Orlistat—Vision blurred—Prednisone—systemic scleroderma	0.000404	0.000654	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—systemic scleroderma	0.000403	0.000653	CcSEcCtD
Orlistat—Diarrhoea—Lisinopril—systemic scleroderma	0.000403	0.000653	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—CSK—systemic scleroderma	0.000401	0.00245	CbGpPWpGaD
Orlistat—Ill-defined disorder—Prednisone—systemic scleroderma	0.000397	0.000644	CcSEcCtD
Orlistat—FASN—Metabolism—HSPG2—systemic scleroderma	0.000392	0.00239	CbGpPWpGaD
Orlistat—Angioedema—Prednisone—systemic scleroderma	0.000391	0.000634	CcSEcCtD
Orlistat—Dizziness—Lisinopril—systemic scleroderma	0.000389	0.000631	CcSEcCtD
Orlistat—Nausea—Mycophenolic acid—systemic scleroderma	0.000388	0.000629	CcSEcCtD
Orlistat—Malaise—Prednisone—systemic scleroderma	0.000386	0.000626	CcSEcCtD
Orlistat—Vertigo—Prednisone—systemic scleroderma	0.000385	0.000624	CcSEcCtD
Orlistat—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00038	0.000616	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000378	0.00231	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ITGAM—systemic scleroderma	0.000377	0.0023	CbGpPWpGaD
Orlistat—Vomiting—Lisinopril—systemic scleroderma	0.000374	0.000607	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—systemic scleroderma	0.000371	0.000602	CcSEcCtD
Orlistat—Rash—Lisinopril—systemic scleroderma	0.000371	0.000602	CcSEcCtD
Orlistat—Convulsion—Prednisone—systemic scleroderma	0.000371	0.000602	CcSEcCtD
Orlistat—Dermatitis—Lisinopril—systemic scleroderma	0.000371	0.000601	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00037	0.000601	CcSEcCtD
Orlistat—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00037	0.0006	CcSEcCtD
Orlistat—Headache—Lisinopril—systemic scleroderma	0.000369	0.000598	CcSEcCtD
Orlistat—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000365	0.000591	CcSEcCtD
Orlistat—Myalgia—Prednisone—systemic scleroderma	0.000365	0.000591	CcSEcCtD
Orlistat—Anxiety—Prednisone—systemic scleroderma	0.000363	0.000589	CcSEcCtD
Orlistat—Alopecia—Methotrexate—systemic scleroderma	0.000363	0.000589	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000362	0.000587	CcSEcCtD
Orlistat—Discomfort—Prednisone—systemic scleroderma	0.00036	0.000584	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—systemic scleroderma	0.00036	0.000584	CcSEcCtD
Orlistat—DAGLA—Hemostasis—TGFB1—systemic scleroderma	0.00036	0.0022	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TGFB1—systemic scleroderma	0.00036	0.0022	CbGpPWpGaD
Orlistat—Malnutrition—Methotrexate—systemic scleroderma	0.000358	0.00058	CcSEcCtD
Orlistat—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000353	0.000572	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—systemic scleroderma	0.00035	0.000568	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—CCL2—systemic scleroderma	0.00035	0.00214	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCL2—systemic scleroderma	0.00035	0.00214	CbGpPWpGaD
Orlistat—Nausea—Lisinopril—systemic scleroderma	0.00035	0.000567	CcSEcCtD
Orlistat—Anaphylactic shock—Prednisone—systemic scleroderma	0.000349	0.000567	CcSEcCtD
Orlistat—Oedema—Prednisone—systemic scleroderma	0.000349	0.000567	CcSEcCtD
Orlistat—Infection—Prednisone—systemic scleroderma	0.000347	0.000563	CcSEcCtD
Orlistat—Back pain—Methotrexate—systemic scleroderma	0.000346	0.000561	CcSEcCtD
Orlistat—Nervous system disorder—Prednisone—systemic scleroderma	0.000343	0.000556	CcSEcCtD
Orlistat—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000341	0.000553	CcSEcCtD
Orlistat—Skin disorder—Prednisone—systemic scleroderma	0.000339	0.00055	CcSEcCtD
Orlistat—Hyperhidrosis—Prednisone—systemic scleroderma	0.000338	0.000548	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—systemic scleroderma	0.000337	0.000547	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000332	0.000538	CcSEcCtD
Orlistat—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000328	0.000531	CcSEcCtD
Orlistat—Rash—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000527	CcSEcCtD
Orlistat—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000527	CcSEcCtD
Orlistat—Headache—Mycophenolate mofetil—systemic scleroderma	0.000323	0.000524	CcSEcCtD
Orlistat—Malaise—Methotrexate—systemic scleroderma	0.000323	0.000523	CcSEcCtD
Orlistat—Vertigo—Methotrexate—systemic scleroderma	0.000322	0.000521	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000318	0.000516	CcSEcCtD
Orlistat—Insomnia—Prednisone—systemic scleroderma	0.000316	0.000512	CcSEcCtD
Orlistat—Paraesthesia—Prednisone—systemic scleroderma	0.000314	0.000509	CcSEcCtD
Orlistat—Cough—Methotrexate—systemic scleroderma	0.000312	0.000506	CcSEcCtD
Orlistat—Convulsion—Methotrexate—systemic scleroderma	0.00031	0.000503	CcSEcCtD
Orlistat—Dyspepsia—Prednisone—systemic scleroderma	0.000308	0.000499	CcSEcCtD
Orlistat—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000306	0.000497	CcSEcCtD
Orlistat—Myalgia—Methotrexate—systemic scleroderma	0.000305	0.000494	CcSEcCtD
Orlistat—Chest pain—Methotrexate—systemic scleroderma	0.000305	0.000494	CcSEcCtD
Orlistat—Decreased appetite—Prednisone—systemic scleroderma	0.000304	0.000493	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—EDN1—systemic scleroderma	0.000303	0.00185	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EDN1—systemic scleroderma	0.000303	0.00185	CbGpPWpGaD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000303	0.000491	CcSEcCtD
Orlistat—Fatigue—Prednisone—systemic scleroderma	0.000301	0.000489	CcSEcCtD
Orlistat—Discomfort—Methotrexate—systemic scleroderma	0.000301	0.000488	CcSEcCtD
Orlistat—FASN—Metabolism—CTGF—systemic scleroderma	0.000297	0.00181	CbGpPWpGaD
Orlistat—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000292	0.000474	CcSEcCtD
Orlistat—Infection—Methotrexate—systemic scleroderma	0.00029	0.00047	CcSEcCtD
Orlistat—Feeling abnormal—Prednisone—systemic scleroderma	0.000288	0.000467	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—systemic scleroderma	0.000286	0.000464	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000286	0.00175	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000286	0.000463	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—systemic scleroderma	0.000284	0.00046	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000282	0.000458	CcSEcCtD
Orlistat—Urticaria—Prednisone—systemic scleroderma	0.000278	0.00045	CcSEcCtD
Orlistat—Abdominal pain—Prednisone—systemic scleroderma	0.000276	0.000448	CcSEcCtD
Orlistat—Body temperature increased—Prednisone—systemic scleroderma	0.000276	0.000448	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000266	0.000431	CcSEcCtD
Orlistat—Insomnia—Methotrexate—systemic scleroderma	0.000264	0.000428	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—systemic scleroderma	0.000262	0.000425	CcSEcCtD
Orlistat—Hypersensitivity—Prednisone—systemic scleroderma	0.000257	0.000417	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—systemic scleroderma	0.000257	0.000417	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—systemic scleroderma	0.000254	0.000412	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—RHOB—systemic scleroderma	0.000253	0.00154	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000252	0.000409	CcSEcCtD
Orlistat—Fatigue—Methotrexate—systemic scleroderma	0.000252	0.000408	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—EDN1—systemic scleroderma	0.000251	0.00153	CbGpPWpGaD
Orlistat—Asthenia—Prednisone—systemic scleroderma	0.000251	0.000407	CcSEcCtD
Orlistat—Pain—Methotrexate—systemic scleroderma	0.00025	0.000405	CcSEcCtD
Orlistat—Pruritus—Prednisone—systemic scleroderma	0.000247	0.000401	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—systemic scleroderma	0.000241	0.00039	CcSEcCtD
Orlistat—Diarrhoea—Prednisone—systemic scleroderma	0.000239	0.000388	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000239	0.000387	CcSEcCtD
Orlistat—Urticaria—Methotrexate—systemic scleroderma	0.000232	0.000376	CcSEcCtD
Orlistat—Dizziness—Prednisone—systemic scleroderma	0.000231	0.000375	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—systemic scleroderma	0.000231	0.000374	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—systemic scleroderma	0.000231	0.000374	CcSEcCtD
Orlistat—Vomiting—Prednisone—systemic scleroderma	0.000222	0.00036	CcSEcCtD
Orlistat—Rash—Prednisone—systemic scleroderma	0.00022	0.000357	CcSEcCtD
Orlistat—Dermatitis—Prednisone—systemic scleroderma	0.00022	0.000357	CcSEcCtD
Orlistat—Headache—Prednisone—systemic scleroderma	0.000219	0.000355	CcSEcCtD
Orlistat—PNLIP—Disease—NOS3—systemic scleroderma	0.000218	0.00133	CbGpPWpGaD
Orlistat—Hypersensitivity—Methotrexate—systemic scleroderma	0.000215	0.000349	CcSEcCtD
Orlistat—Asthenia—Methotrexate—systemic scleroderma	0.00021	0.00034	CcSEcCtD
Orlistat—Nausea—Prednisone—systemic scleroderma	0.000208	0.000337	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CCL2—systemic scleroderma	0.000207	0.00126	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCL2—systemic scleroderma	0.000207	0.00126	CbGpPWpGaD
Orlistat—Pruritus—Methotrexate—systemic scleroderma	0.000207	0.000335	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—systemic scleroderma	0.0002	0.000324	CcSEcCtD
Orlistat—PLA2G4A—Betamethasone—Mometasone—systemic scleroderma	0.0002	0.00941	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Mometasone—systemic scleroderma	0.0002	0.00941	CbGdCrCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000197	0.0012	CbGpPWpGaD
Orlistat—Dizziness—Methotrexate—systemic scleroderma	0.000193	0.000313	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—SMAD7—systemic scleroderma	0.000193	0.00118	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MMP1—systemic scleroderma	0.000189	0.00115	CbGpPWpGaD
Orlistat—Vomiting—Methotrexate—systemic scleroderma	0.000186	0.000301	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—NOS3—systemic scleroderma	0.000184	0.00113	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NOS3—systemic scleroderma	0.000184	0.00113	CbGpPWpGaD
Orlistat—Rash—Methotrexate—systemic scleroderma	0.000184	0.000299	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—systemic scleroderma	0.000184	0.000298	CcSEcCtD
Orlistat—Headache—Methotrexate—systemic scleroderma	0.000183	0.000297	CcSEcCtD
Orlistat—PNLIP—Metabolism—NOS3—systemic scleroderma	0.000183	0.00112	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000176	0.00107	CbGpPWpGaD
Orlistat—Nausea—Methotrexate—systemic scleroderma	0.000173	0.000281	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CCL2—systemic scleroderma	0.000172	0.00105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HSPG2—systemic scleroderma	0.000168	0.00103	CbGpPWpGaD
Orlistat—FASN—Disease—NOS3—systemic scleroderma	0.000154	0.000943	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NOS3—systemic scleroderma	0.000153	0.000933	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RHOB—systemic scleroderma	0.000149	0.000911	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—systemic scleroderma	0.000148	0.000904	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—systemic scleroderma	0.000148	0.000904	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFB1—systemic scleroderma	0.000144	0.000881	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HSPG2—systemic scleroderma	0.000141	0.000859	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS3—systemic scleroderma	0.000137	0.000836	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CSK—systemic scleroderma	0.000136	0.00083	CbGpPWpGaD
Orlistat—FASN—Metabolism—NOS3—systemic scleroderma	0.000129	0.00079	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EDN1—systemic scleroderma	0.000129	0.000787	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CTGF—systemic scleroderma	0.000128	0.000778	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—systemic scleroderma	0.000123	0.000749	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—systemic scleroderma	0.000122	0.000745	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—systemic scleroderma	0.000122	0.000745	CbGpPWpGaD
Orlistat—PLA2G4A—Betamethasone—Prednisone—systemic scleroderma	0.000109	0.00513	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Prednisone—systemic scleroderma	0.000109	0.00513	CbGdCrCtD
Orlistat—FASN—Disease—TGFB1—systemic scleroderma	0.000102	0.000623	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—systemic scleroderma	0.000101	0.000617	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—systemic scleroderma	9.05e-05	0.000553	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL2—systemic scleroderma	8.82e-05	0.000538	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EDN1—systemic scleroderma	7.62e-05	0.000465	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NOS3—systemic scleroderma	5.55e-05	0.000339	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL2—systemic scleroderma	5.21e-05	0.000318	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOS3—systemic scleroderma	4.64e-05	0.000283	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.94e-05	0.000241	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—systemic scleroderma	3.72e-05	0.000227	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—systemic scleroderma	3.07e-05	0.000187	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.99e-05	0.000182	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.3e-05	7.94e-05	CbGpPWpGaD
